This Shooting Star Shows No Sign Of Slowing Down

Daniel Cross - INO.com Contributor - Equities


Value investors love finding a small cap stock that's outperforming while flying under the radar. Wall Street analysts tend to focus on larger companies which means their smaller counterparts can often be mispriced – a scenario that value hunters live for.

Finding an undervalued stock in an industry that's growing fast as well is like having your cake and eating it too.

The US hosts the largest medical supplies market in the world valued at around $110 billion and expected to reach $133 billion by next year. The US constituted 38% of the worldwide medical equipment market (as of 2012) and exports are expected to rise over the next several years even in the face of a challenging environment driven by the high relative value of the dollar. Continue reading "This Shooting Star Shows No Sign Of Slowing Down"

McKesson Delivers Another Steller Quarterly Report

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction

McKesson Corporation (MCK) reported quarterly results last week and beat on both the top and bottom line while raising guidance and announcing a massive $2 billion share buyback program. The stock responded with a yawn and now sets around $180 per share. MCK presents a compelling investment opportunity in the healthcare space, particularly after the recent sell-off from $243 to $180 per share. This downward movement was flanked by great earnings reports, increased dividend and additional share buybacks. MCK continues to become cheaper and cheaper as each earnings report is announced and the company continues to purchase additional shares. McKesson looks to be undervalued given its growth rate, acquisitive mindset, attractive P/E, dividend and share buyback program. I previously wrote an article outlining my bull case for McKesson and since then the stock has only become cheaper. I feel McKesson is a buy below $200 per share.

McKesson's Blowout Quarterly Results

McKesson reported revenue of $58.8 billion which translates into a 10% increase from the prior fiscal year quarter. On top of this revenue growth, earnings per share increased 19%, cash, and cash equivalents reached $5.2 billion, the company initiated a $2 billion share buyback program and raised guidance from $12.36-$12.86 to $12.50-$13.00 per share. All of these attributes bode well for investors, and now McKesson has a trailing 12 month EPS of $8.26 and with a current price of $179 this translates into a P/E of 21.7. This is an attractive P/E given its shareholder-friendly capital return plan via dividends and share buybacks along with its growth. Continue reading "McKesson Delivers Another Steller Quarterly Report"

McKesson Corporation Presents A Compelling Investment Opportunity

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction

McKesson Corporation (MCK) presents a compelling investment opportunity in the healthcare space, particularly after the recent sell-off from $243 to below $200 per share. In brief, McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technology. The Company operates in two segments. The McKesson Distribution Solutions segment distributes drugs, equipment and health and beauty care products domestically and internationally. This segment provides pharmaceutical solutions for biotech and pharmaceutical manufacturers, and practice management, technology, clinical support and business solutions to oncology and other specialty practices operating in the community setting. The McKesson Technology Solutions segment includes McKesson Health Solutions, which includes clinical solutions, claims payment solutions and network performance tools. This segment delivers enterprise-wide clinical, patient care, financial, supply chain, strategic management software solutions, as well as connectivity, outsourcing and other services.

McKesson is driving growth via acquisitions and partnerships

MCK recently acquired the pharmaceutical distribution division of UDG Healthcare plc for €408 million in cash. This acquisition will add a leader in pharmaceutical distribution across the Republic of Ireland and Northern Ireland to McKesson's European business. Marc Owen, Chairman of the Management Board at Celesio AG, said: "The acquisition of UDG's pharmaceutical distribution, home and travel healthcare businesses in Ireland and the UK, will strengthen our position in the industry. We have made this investment as part of our growth strategy which leverages the positive trajectory of the wider healthcare sector in Europe. This acquisition will also complement our broader portfolio of assets in both Ireland and the United Kingdom. We look forward to continuing UDG's tradition of excellent customer service and to working with the UDG team." Continue reading "McKesson Corporation Presents A Compelling Investment Opportunity"